- Tyme Stock
- Tyme Curling Iron
What this means: Tyme Technologies (TYME) gets an Overall Rank of 54, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. TYME's 54 means that it ranks higher than 54% of stocks.
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. You need to enable JavaScript to run this app. Internet Banking. You need to enable JavaScript to run this app. The Tyme For Companies program is a managed food program that services the most forward-thinking companies in your area. We allow all restaurants on our platform to opt-in and receive larger catering and food program orders from these great companies.
Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.
FundamentalPREMIUM
Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.
Upgrade to Premium to unlock Fundamental Ranking
Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.
Upgrade to Premium to unlock Short-Term Technical Ranking
Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.
Upgrade to Premium to unlock Long-Term Technical Ranking
Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.
Upgrade to Premium to unlock Analyst Ranking Analysis
Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.
Upgrade to Premium to unlock Valuation Ranking
Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.
Upgrade to Premium to unlock Stock Sentiment Ranking
What this means: Tyme Technologies (TYME) gets an Overall Rank of 54, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. TYME's 54 means that it ranks higher than 54% of stocks.
Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.
Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.
Upgrade to Premium to unlock Fundamental Ranking
Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.
Upgrade to Premium to unlock Short-Term Technical Ranking
Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.
Upgrade to Premium to unlock Long-Term Technical Ranking
Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.
Upgrade to Premium to unlock Analyst Ranking Analysis
Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.
Upgrade to Premium to unlock Valuation Ranking
Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.
Upgrade to Premium to unlock Stock Sentiment Ranking
Tyme Technologies (TYME) Analyst Forecast
- Last Price$1.44
- Previous Close $1.33
- Change$0.11
- Open$1.33
- Volume1,112,913
- Avg. Volume (100-day)7,438,687
- Market Cap245,415,008
- Days Range1.3 - 1.47
- 52-week Range0.85 - 4.99
- Dividend Yield —
- Ex. Dividend Date —
- P-E—
- EPS—
- Earnings Date 05/19/21
- SectorHealthcare
- IndustryBiotechnology
- Avg. Analyst Rec. Premium
- Beta2.287
- PEG Ratio—
Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.
Tyme Stock
My Watchlists
Follow Your Favorite Stocks
Top Stocks in Biotechnology
Tyme Curling Iron
Company | Price |
GT Biopharma Inc (GTBP)(GTBP) | $9.39 |
Seelos Therapeutics Inc (SEEL)(SEEL) | $5.45 |
Affimed N.V. (AFMD)(AFMD) | $9.54 |
Protalix Biotherapeutics (PLX)(PLX) | $5.74 |
Lineage Cell Therapeutics Inc (LCTX)(LCTX) | $2.34 |
Sol-Gel Technologies Ltd (SLGL)(SLGL) | $14.00 |
Ardelyx Inc (ARDX)(ARDX) | $7.91 |
Protagonist Therapeutics Inc (PTGX)(PTGX) | $27.49 |
Essa Pharma (EPIX)(EPIX) | $26.03 |
Cara Therapeutics (CARA)(CARA) | $27.89 |